The Role of Beetroot Extract in Overcoming Chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide Regimen by Targeting Immune Response in Tumor Microenvironment: A Preclinical Study in Mammary Adenocarcinoma Rats

Sri Susilowati1,2*, Hermawan Istiadi3, Suhartono Suhartono4, Yan Wisnu Prajoko5, Ignatius Riwanto6, Neni Susilaningsih7, Catharina Suharti8

Abstract

Objective: This study aims to determine the role of beetroot extract in overcoming the chemoresistance of Neoadjuvant Adriamycin Cyclophosphamide (NAC) regimens with a target immune response in the tumour microenvironment at the pre-clinical stage. Methods: This study was conducted on rats with 7,12-Dimethyl Benz (α) Anthracene (DMBA) induced mammary adenocarcinoma. Adriamycin Cyclophosphamide was given in 4 cycles, whereas beetroot extract was administered three times each cycle. Observations of CD8 T cells and Myeloid Derivative Suppressive Cells (MDSC) expression levels and pathological responses were carried out on tumour tissue taken at the end of the observation. Results: Supplementation of beetroot extract to NAC could significantly increase CD8 T cells and decrease MDSC in the tumour microenvironment. The addition of beetroot extract gave a better pathological response. Conclusion: Beetroot extract enhances the immune response in the tumor microenvironment so that it has the potential to overcome chemoresistance in NAC.

Keywords: Beetroot- neoadjuvant- adriamycin- cyclophosphamide- CD8- T cells- myeloid derivative suppressive

Introduction

Breast cancer is the most common type of cancer diagnosed in women worldwide with high incidence and mortality (IARC, 2020). The currently available therapeutic modalities are surgery, radiotherapy, chemotherapy or targeted therapy. Chemotherapy is classified as systemic therapy (Miller et al., 2014). Chemoresistance is one of the obstacles to be good therapeutic outcome so causing the risk of relapse in breast cancer treatment. The mechanism of chemoresistance in breast cancer involves drug absorption on cell membranes, transporter proteins, oncogenes and tumor suppressor genes, DNA repair, stem cells, Tumor Microenvironment (TME) and Epithelial-Mesenchymal-Transition (EMT) (Ji et al., 2019; Lainetti et al., 2020). Stromal cells such as fibroblasts, immune cells, vascular endothelial cells, and other components such as the extracellular matrix present in TME have a role in tumour response to chemotherapy. Tumour-Associated Macrophage (TAM) and Tumour-Infiltrating Lymphocytes (TIL) are immune cells in TME associated with chemoresistance (Velaei et al., 2016). Chemoresistance can be overcome through gene therapy or immune therapy approaches (Ji et al., 2019).

Neoadjuvant Adriamycin Cyclophosphamide (NAC) regimen is one of standard anthracycline-based breast cancer therapy that still recommended for patients with locally advanced breast cancer before surgery (Cardoso et al., 2017; Miller et al., 2014; Senkus et al., 2015). This regimen is given to reduce the size of the tumour so that surgery is possible. Using the Adriamycin Cyclophosphamide (AC) regimen as a neoadjuvant resulted in clinical and pathological responses of 40.1% and 13.7% and increased to 63.6 and 26.1% after adding docetaxel (Bear et al., 2003). The addition of bevacizumab to the neoadjuvant nab-paclitaxel with AC...
improves the pathologic complete response (pCR) in inflammatory or locally advanced breast cancer (Nahleh et al., 2016). The results of a meta-analysis of patients receiving anthracycline-based NAC overall showed pCR and breast-conserving surgery outcomes of 26.5% and 70.6%, respectively (Kang et al., 2021). There is currently sufficient evidence that if NAC leads to a complete pathological response, it will have a good therapeutic outcome (Masood, 2016).

Adriamycin Cyclophosphamide is a cytostatic agent with a DNA-damaging mechanism (Sidid, 2002; Tacar et al., 2013). Chemoresistance to NAC involving immune cells in TME is currently only known from TAM, which is form differentiation from immature myeloid cells, Myeloid derivatives Suppressive Cells (MDSC). Overexpression of M2, a pro-tumorigenic macrophage in TME, is associated with an absent clinical response in patients with anthracycline-based NAC (Litviakov et al., 2018). Chemotherapy doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² given every 2 weeks can increase MDSC in peripheral blood circulation (Bracci et al., 2014). Tumor-infiltrated MDSCs have been shown to correlate with clinical pathology, chemotherapy response and prognosis of breast cancer patients (Li et al., 2018). MDSCs in experimental animals such as rat can be identified through the expression of the biomarker CD11b (Condamine and Gabriovich, 2011). TIL, primarily CD8 T cells, and MDSC cells are immune cells that act opposite in TME. CD8 cytotoxic T cell activity produces an antitumor immune response, whereas MDSC cells have an immunosuppressive role (Dieci et al., 2021). In carcinogen-induced adenocarcinoma and fibrosarcoma trials, Doxorubicin can increase CD8 T cell proliferation in lymph nodes and increase CD8 T cell infiltration through IFN-γ secretion (Bracci et al., 2014). However, there has no study of the effect of NAC therapy on CD8 T cells but CD8 TIL can be used as a predictive factor for pCR of primary breast cancer patients receiving anthracycline-based systemic therapy (Seo et al., 2013).

In recent years, the use of phyotherapy products as complementary treatment by women with a history of breast cancer has increased significantly. However, scientific evidence of its efficacy and safety is still lacking (Drozdoff et al., 2018; Lopes et al., 2017). One of the herbal products that has been empirically used with systemic breast cancer therapy is beetroot. This study aims to provide scientific evidence at the pre-clinical stage about the benefits of beetroot extract in overcoming NAC chemoresistance involving immune cells in TME. In this study revealed the efficacy of NAC after adding beetroot extract to the pathological response as the endpoint of observation. Pathologic complete response (pCR) was used as the endpoint in most studies looking at the NAC response (Parekh et al., 2015). Clinically, pCR assessment can use a variety of different standards. pCR can also be obtained from evaluating the proportion of fibrosis to tumour cells described in the absence of tumour cells and mostly fibrosis, or tumour cells are sparse and scattered throughout the fibrosis (Frentzas et al., 2019).

Beetroot which contains the main active compound betalain has bioactivity such as anti-inflammatory, antioxidant, immunomodulatory, and cancer chemopreventive properties. The immunomodulatory activity of betalain through increased proliferation of spleen lymphocytes, phagocytic function of peritoneal macrophages, and NK cell activity in vitro, also increased the immune organ index and serum hemolysin, and improved biochemical indices in vivo (Fu et al., 2020). The results of in vivo studies on experimental animals showed that the administration of beetroot extract significantly reduced DNA damage and increased the proliferation of hematopoietic progenitor cells in C57BL/6 mice exposed to γ-ray radiation for 10 days (Cho et al., 2017). Research on the inflammatory activity related to the immune response of beetroot extract has also been carried out. The anti-inflammatory effects of beetroot betalains are well known in vitro (Reddy et al., 2005; Vidal et al., 2014) or in vivo (Asgary et al., 2016; El Gamal et al., 2014; Pietrzkowski et al., 2010; Tan et al., 2015). Betalains can reduce levels of pro-inflammatory cytokine proteins such as TNF-, IL-6, IL-8, and IL-1β, reactive oxygen, as well as COX-2 and lipoxygenase (LOX) enzyme activities, causing a reduction in PGE2 and LOX-5. Even betacyanin and betaxanthin can decrease the activity of transcription factor activator protein and NF-kB (Clifford et al., 2015). Based on the results of this study, beetroot extract herbal can be used to overcome chemoresistance with immune cells in TME as a target, particularly by observing the expression of CD8 and CD11b biomarkers as well as the primary outcome in the form of response pathology.

**Materials and Methods**

Beetroot extract was obtained from Tokyo Chemical Industri, Co., Ltd, Tokyo Japan under trade name Betanine and Catalog Number B0397. Adriamycin (DoxorubicinR) and Cyclophosphamide (CytoxanR) was obtained from PT. Kalbe Farma. Animal used Sprague Dawley female rats that was obtained from National Center for Drug and Food Testing Development, Food and Drug Supervisory Agency of the Republic of Indonesia and being treated in the laboratory of Animal Research Facilities, Faculty of Medicine, University of Indonesia. Ethical approval was obtained from The Ethics Committee of the Faculty of Medicine, University of Indonesia with number: KET-756/UN2.F1/ETIK/PPM.00.02/2019.

**Carcinogenesis**

Carcinogenic agent for cancer induction: 7,12-dimethyl benz (α) anthracene (DMBA) from Sigma Aldrich with corn oil solvent. Cancer induction for 5 weeks at a dose of DMBA 20 mg/kg BW, orally, 2 times a week in forty days old rats.

**Design Study**

This was an experimental study with a Randomized Post test only Control Group Design. Twenty-four rats with nodule diameter tumor more than 10 mm were randomized allocated into 4 treatment groups, without treatment as negative control, AC only treatment at dose 5 mg/kg BW for Adriamycin and 50 mg/kg BW for Cyclophosphamide, intraperitoneally, weekly during 4
cycle, and 2 groups AC treatment with supplementation beetroot extract, orally, 3 times a week at dose 25 mg/kg BW, and 100 mg/kg BW, respectively. At the end of the 4th week, the rats were necropsied for tumor tissue for examination of CD8, CD11b expression levels and pathological responses.

**Determination of CD8 and CD11b expression levels using the qRT-PCR method**

Determination of CD8 and CD11b expression levels were used paraffin embedded tissue slices using the qRT-PCR method. The template in this study used mRNA, where the mRNA isolation was carried out according to the Protocol for total RNA purification with On-column DNase I treatment from animal tissue from Gene AllIR (GeneAll Biotechnology, 2016). The qRT-PCR amplification process used the AccuPower® Green StarTM RT-qPCR Kit with the following primer design: CD8 forward primer sequence 5'-ACTTGTTGGGTCCTTCCTC-3' and CD8 reverse primer sequence 5'-TCTCCCGATTCCACACAG-3' also CD11b forward primer sequence 5'-ATGGACGCTGATGCAATACC-3' and CD11b reverse primer sequence 5'-TCCCCATTCAGCTTCTCCA-3'. qRT-PCR examination using Bioneer Exicycler 96TM with 40-45 cycling, begins with reverse transcription at 60°C for 15 minutes, pre denaturation at 95°C for 3–5 minutes, denaturation at 95°C for 5-30 seconds, annealing at 60°C for 5-30 seconds, and melting according to manual protocol. Data from qRT-PCR were analyze using the 2^(-ΔΔCT) method, which were presented as the fold change in gene expression normalized to an endogenous reference gene GAPDH and relative to normal mammary tissue (Livak and Schmittgen, 2001).

**Pathological Response Assesment**

Pathological response is a tumor response that is assessed from tumor tissue stained with Hematoxylin Eosin based on the tumor regression grade (TRG 1-5) of the assessment of the proportion of fibrosis to tumor cells on tissue slice preparations with HandE staining, as follows TRG 1 = no tumor cells and mostly fibrosis, TRG 2 = the presence of rare and scattered tumor cells throughout the fibrosis, TRG 3 = more residual tumor cells but fibrosis predominates, TRG 4 = residual cancer cells predominate over fibrosis, TRG 5 = no signs of tumor regression. The grouping of the 3 main pathological responses is as follows: Complete Response = TRG 1-2, Partial Response = TRG 3, No Response = TRG 4-5 (Frentzas et al., 2019).

**Statistical Analysis**

The CD8 and CD11b expression level data were analyzed by ANOVA followed by post-hoc-test (Tukey-HSD). Pathological Response was analyzed using the Chi-Square test. The correlation test of CD8, CD11b expression levels with pathological responses was used Spearman’s rho test.

**Results**

Characteristics of tumor tissue-based on examination of histopathological showed that tumour that occurred in the mammae of these rats was classified as mammary adenocarcinoma, meaning that the tumour caused by DMBA induction was cancer. The cancer subtypes were ductal carcinoma, cribriform carcinoma and invasive papillary carcinoma, but unfortunately the limitation of this study was that the examination of tumor type was carried out after the intervention. In the negative control group (C1), there was one rat with histopathological characteristics of fibroadenoma, so it was excluded as a study sample. In the treatment group of AC plus beetroot extract at a dose of 100 mg/kg BW (P2) there was one rat in which the nodule or tumour disappeared on the 3rd week, so no tumour tissue could be obtained. The number of final samples for the examination of molecular targets and pathological responses was 22 rats. The research CONSORT was presented in Figure 1.

**Effect of addition of beetroot extract on CD8 and CD11b expression levels**

The CD8 expression levels of the AC plus beetroot extract either at a dose of 25 mg/kg BW or 100 mg/kg BW treatment groups were significantly higher (p=0.000 and p=0.000) than the AC only treatment group (Figure 2). This proves that beetroot extract affects the number of CD8 cytotoxic T cells in TME. The difference in the dose of beetroot extract affected the CD8 expression level, proven by a significantly higher result (p=0.000) in the dose 100 mg/kg BW group compared to the 25 mg/kg BW group. The CD8 expression level of the AC only treatment group was higher but not significantly (p=0.305) than the negative control group, indicating that the AC at this dose did not affect CD8 expression level. Meanwhile CD8 expression level in the group given AC plus beetroot extract either at dose of 25 mg/kg BW or 100 mg/kg BW was significantly higher (p=0.000) than the negative control group. This further proves that beetroot

### Table 1. Pathological Response Evaluation Results

| Treatment Group | Pathologic Response (n) | Response | No response |
|-----------------|------------------------|----------|------------|
| Group C1        | CR 0                   | PR 0     | NR 5       | 5           |
|                 |                        |          |            |
| Group C2        | CR 0                   | PR 0     | NR 3       | 3           |
|                 |                        |          |            |
| Group P1        | CR 1                   | PR 3     | NR 2       | 4           |
|                 |                        |          |            |
| Group P2        | CR 1                   | PR 4     | NR 0       | 0           |

Note: Group C1, negative control, without treatment, Group C2 : AC only control, Group P1 : AC+ Beetroot extract at a dose 25 mg/kg BW treatment, Group P2: AC + Beetroot Extract at a dose 100 mg/kg BW Treatment; CR, Complete Response, PR, Partial response

### Table 2. Summary of Correlation Test Results on Pathological Response Variable

| Independent variable | Correlation value (R) | P value |
|----------------------|-----------------------|---------|
| CD8                  | 0.542                 | 0.009   |
| CD11b                | -0.660                | 0.001   |

Note: Spearman's rho correlation test, significant if p <0.05. Spearman’s rho correlation degree: very weak (0-0.25); enough (0.26-0.5); (0.51-0.75) strong; 0.76-0.99 is very strong; 1 perfect correlation.
extract given with neoadjuvant AC regimen can affect CD8 expression level in TME.

The results showed that the CD11b expression level in the AC plus beetroot extract treatment group was lower than the AC only treatment group, but only for the beetroot extract at a dose 100 mg/kg BW group

Figure 1. Consolidation of Report Trial

Figure 2. Comparison graph of CD8 Expression Levels (mean ± SD) between Treatment Groups. The results of ANOVA followed by Post Hoc-Test, were significant if p < 0.05: * : significantly different from Group C2 with p value = 0.000 for group P1 and p = 0.000 for group P2. @: significantly different from Group C1 with a value of p = 0.000 for group P1 and p = 0.000 for group P2. #: significantly different from the P1 group with p value = 0.000.
The Role of Beetroot Extract

which was statistically significant (p=0.012) (Figure 3). When compared with the negative control group, CD11b expression level in the AC only treatment group showed lower but not significant (p=0.158), while in the group that was given AC plus beetroot extract at doses of 25 mg/kg BB or 100 mg/kg BW was significantly lower (p=0.006 and p=0.000). This proves that addition of beetroot extract to NAC affects the level expression of CD11b. However the difference in the dose of beetroot extract did not affect CD11b expression because CD11b expression level in the AC plus beetroot extract at a dose 100 mg/kg BW was lower but not significant (p=0.249) than a dose 25 mg/kg BW. Thus it can be stated that the addition of beetroot extract to NAC can reduce MDSC, because the CD11b biomarker is a feature of MDSC in rat.

Effect of addition of beetroot extract on pathological response

AC only treatment without beetroot extract showed a different pathological response but not significantly compared to negative control without any treatment (p = 0.064). The addition of beetroot extract to the AC regimen showed a different and significant pathological response compared to negative control (p=0.022 and p=0.002) (Table 1). This shows that the addition of beetroot extract to the AC regimen can improve the pathological response of tumor cells. Actually, when compared to the AC group only, the pathological response of the AC plus beetroot extract group was better but not significant statistically (p=0.558 and p=0.064). Histopathological description of mammary tumor tissue with Hematoxylin and Eosin (H&E) staining in each treatment group

Figure 3. Comparison Graph of CD11b Expression Levels (mean ± SD) between Treatment Groups. The results of ANOVA continued with Post Hoc Test, meaningful if p < 0.05: * : significantly different from Group C2 with p-value = 0.012. @ was significantly different from Group C1 with p = 0.006 for Group P1 and p = 0.000 for Group P2.

Figure 4. The Representative Image of H&E Staining from Tumor Sample in Each Group (magnification 400x). A, Group C1, negative control without treatment; B, Group C2, AC only treatment; C, Group P1, AC + Beetroot extract at a dose 25 mg/kgBW treatment; D, Group P2, AC + Beetroot extract at a dose 100 mg/kgBW treatment.
showed differences (Figure 4).

The results of the correlation test between each expression level variable CD8 and CD11b with a pathological response showed a correlation (p<0.05) (Table 2). The direction of the negative relationship is shown in the expression of CD11b, meaning that the lower the expression level of CD11b make better the pathological response. A positive relationship was shown in CD8 expression, meaning that the higher the CD8 expression level, make better the pathological response. The degree of correlation between CD8 and CD11b expression with pathological response was strong.

Discussion

The low pathologic Complete Response results in the treatment of NAC in breast cancer patients could be attributed to chemoresistance. NAC chemoresistance involving immune cells in TME is associated with an increase in MDSC and overexpression of macrophage M2 (Bracci et al., 2014; Litviakov et al., 2018). High MDSCs in TME lead to tumor growth, because MDSC activity can inhibit the cytolytic function of CD8 T cells either through metabolic pathways that involve amino acids for T cell activity and proliferation, or inhibits T cell apoptosis (Law et al., 2020). CD8 T cells are effector cells that kill cancer cells by releasing granzyme and perforin and Fas ligands for the process of apoptosis. The CD8 T cells expansion occur from the lymph nodes to the circulation and TME which its activity begins with the introduction of antigens by Antigen Presenting Cell (APC), namely dendritic cells (DC) and is presented through the MHC I complex to CD8 T cells. Whereas MDSCs are immature myeloid cells derived from bone marrow progenitors. MDSC recruitment and accumulation into TME is mediated by cytokines and chemokines such as IL6, IL1-β, TGF-1β, CCL2 which are secreted by tumor cells (Dieci et al., 2021; Ostroumov et al., 2018).

The findings in this study proved that beetroot extract can decrease MDSC and increase CD8 T cells. The ability of beetroot extract to reduce MDSC is thought to be related to its anti-inflammatory activity. Beetroot extract have anti-inflammatory activity against COX2 and PGE, also reduce levels of TNF-α, IL-6, and NFkB (El Gamal et al., 2014). COX2, PGE, IL-6 and NFkB are pro-inflammatory proteins that play a role in MDSC recruitment and activity (Gabrilovich, 2017; Law et al., 2020; Marvel and Gabrilovich, 2015). It is known that pro-inflammatory signaling is also associated with chemoresistance. Elevated levels of IL-6 expression correlate with advanced disease stage and poor prognosis in breast cancer (Das and Law, 2018). Increased NFkB activity is also associated with doxorubicin resistance (Gangadharan et al., 2009). Beside being associated with a decrease in MDSC, the finding that beetroot extract can increase CD8 T cells was also associated with its immunomodulatory activity. Previous studies have shown that beetroot extract can increase the proliferation of splenocytes and hematopoietic progenitor cells in vivo (Cho et al., 2017). Betalain is a constituent that is responsible for the immunomodulatory activity of beetroot extract, particularly in increasing the proliferation of spleen lymphocytes (Fu et al., 2020). CD8 T sel activity also involves other immune cells such as dendritic cells, CD4 T helper cells, TReg, but unfortunately the involvement of these immune cells has not been revealed in this study.

Pathological response is the endpoint for assessing tumor response to NAC. Complete pathological response is the expected therapeutic outcome, because it can keep the patient from relapse (Kunnuru et al., 2020; Parekh et al., 2015). Tumor response to NAC also depends on the molecular subtype of the cancer. Cancer with positive Estrogen Receptor (ER) was less sensitive to DNA damaging chemotherapy such as NAC than ER negative (McDonald et al., 2016; Sharma, 2014). Previous research has shown that characteristics of mammary cancer formed by DMBA induction are similar to luminal A subtypes in human breast cancer, namely the presence of positive ER/PR expression and low Ki-67 (Alvarado et al., 2017). Presumably because of this, the pathological response of NAC in this study was not significant compared to the untreated control. The addition of beetroot extract to NAC was proven to significantly improve the pathological response compared to the untreated control. Based on the results of a strong correlation between the expression levels of CD8 and CD11b with pathological responses in this study, it is suspected that beetroot extract can improve pathological responses due to the involvement of these immune cells, especially the decrease in MDSC and increase in CD8 T cells in TME. Nevertheless the factors that influence the complete pathological response are complex. Because the molecular characteristics of cancer in this study are still limited to the luminal subtype A, the limitation of this study is that the role of beetroot extract in improving the pathological response of NAC when given a progressive cancer molecular subtype is unknown.

As conclusion the addition of beetroot extract in the neoadjuvant AC regimen can improve the pathological response of cancer cells by increasing the immune response in the tumor environment, especially increasing CD8 T cells and decreasing MDSC. This study proves the molecular role of beetroot extract in overcoming the chemoresistance problem caused by the AC regimen as a neoadjuvant. This study provides scientific evidence about the benefits of beetroot extract when given with neoadjuvant regimen AC in cases of breast cancer in the pre-clinical trial stage. The results of the study are expected to be used as a basis for clinical research, thereby providing evidence of the effectiveness of complementary therapies between natural ingredients, namely beetroot extract and the AC regimen in breast cancer patients.

Author Contribution Statement

Substantial contributions to the conception or design of study and analysis or interpretation of data: Sri Susilowati, Catharina Suharti, Neni Susilaningsih, Ignatius Riwanto, Yan Wisnu Prajoko and Suhartono. Investigation: Sri Susilowati, Hermawan Istriadi. Writing – Original Draft Preparation: Sri Susilowati. Writing – Review and Editing: Sri Susilowati, Catharina Suharti, Neni Susilaningsih, Ignatius Riwanto, Yan Wisnu Prajoko, Suhartono.
Acknowledgements

General
I would like to thank the head and staff of laboratories the Animal Research Facilities, IMERI, Faculty of Medicine, Indonesia University, who have provided assistance with the rearing and treatment of the animals in this study, also many thank to the head and staff laboratories Anatomical Pathology Laboratory, Faculty of Medicine, Gadjah Mada University who have provided assistance for qRT-PCR assays in this study. I would like to thank also to the head and staff of laboratories Anatomical Pathology Laboratory, Faculty of Medicine, Diponegoro University who have provide assistance for pathological response assessment.

Funding Statement
This research was funded by Lembaga Pengelola Dana Pendidikan (LPDP), Ministry of Finance, Republic of Indonesia with the grant number: PRJ-6365/LPDP.3/2016.

Approval
It is part of an approved student thesis from Doctoral Program of Medical and Health Sciences, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.

Ethical Declaration
Ethical approval was obtained from The Ethics Committee of the Faculty of Medicine, University of Indonesia with number: KET-756/UN2.F1/ETIK/PPM.00.02/2019.

Conflict of Interest
The authors declare no conflict of interest.

References
Alvarado A, Lopes AC, Faustino-Rocha AI, et al (2017). Prognostic factors in MNU and DMBA-induced mammary tumors in female rats. Pathol Res Pract, 213, 441–6.
Asgary S, Afshani MR, Sahbehkar A, et al (2016). Improvement of hypertension, endothelial function and systemic inflammation following short-term supplementation with red beet (Beta vulgaris L.) juice: A randomized crossover pilot study. J Hum Hypertension, 30, 627–32.
Bear HD, Anderson S, Brown A, et al (2003). The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21, 4165–74.
Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014). Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Different, 21, 15–25.
Cardoso F, Costa A, Senkus E, et al (2017). 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol, 28, 16–33.
Cho J, Bing SJ, Kim A, et al (2017). Beetroot (beta Vulgaris) rescues mice from γ-ray irradiation by accelerating hematopoiesis and curtailing immunosuppression. Pharm Biol, 55, 306–16.
Clifford T, Howatson G, West DJ, Stevenson EJ (2015). The potential benefits of red beetroot supplementation in health and disease. Nutrients, 7, 2801–22.
Condamine T, Gabrilovich DI (2011). Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol, 32, 19–25.
Das M, Law S (2018). Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. Int J Biochem Cell Biol, 103, 115–24.
Decie MV, Miglietta F, and Guarnieri V (2021). Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells, 10, 1–27.
Drozdoff L, Klein E, Kiechle M, Paepeke D (2018). Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Alternat Med, 18, 45–9.
El Gamal AA, Alsaid MS, Raish M, et al (2014). Beetroot (Beta vulgaris L.) Extract Ameliorates Gentamicin-Induced Nephrotoxicity Associated Oxidative Stress, Inflammation, and Apoptosis in Rodent Model. Mediat Inflamm, 2014, 1–12.
Frentzas S, Lum C, Chen T (2019). Angiogenesis and Its Role in the Tumor Microenvironment: A Target for Cancer Therapy. In Current Cancer Treatment. IntechOpen publisher, pp 17.
Fu Y, Shi J, Xie S, et al (2020). Red Beetroot Betalains: Perspectives on Extraction, Processing, and Potential Health Benefits. J Agric Food Chem, 68, 11595-611.
Gabrilovich DI (2017). MDSC: Myeloid-Derived Suppressor Cells. Cancer Immunol Res, 5, 3–8.
Gangadharan C, Thoh M, Manna SK (2009). Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J Cell Biochem, 107, 203–13.
Gene All Biotechnology (2016). Protocol Handbook Ribosip II. GeneAll Biotechnology, Seoul, South Korea, pp 314.
IARC, International Agency for Research on Cancer, (2020). Fact Sheets by Cancer. In GLOBOCAN 2020: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2020.
Ji X, Lu Y, Tian H, et al (2019). Biomedicine and Pharmacotherapy Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharm, 114, 108800.
Kang YK, Si YR, AnGY, Yuan P (2021). Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis. Gland Surg, 10, 252–61.
Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Balaji Singh K (2020). A study on clinical and pathological responses to neoadjuvant chemotherapy in breast carcinoma. Breast Cancer Targets Ther, 12, 259–66.
Lainetti P de F, Leis-Filho AF, Lauffer-Amorim R, Battazza A, Fonseca-Alves C E (2020). Mechanisms of resistance to chemotherapy in breast cancer and possible targets in drug delivery systems. Pharmaceutics, 12, 1–20.
Law AMK, Valdes-Mora F, Gallego-Ortega D (2020). Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells, 9, 561.
Li F, Zhao Y, Wei L, Li S, Liu J (2018). Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther, 19, 695–705.
Litviakov N, Tsyganov M, Larionova I, et al (2018). Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. Cancer Chemotherapy Pharmacol, 82, 99–109.
Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods, 25, 402–8.
Lopes CM, Dourado A, Oliveira R (2017). Phytotherapy and nutritional supplements on breast cancer. *BioMed Res Int*, 2017, 1-42.

Marvel D, Gabrilovich DI (2015). Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. *J Clin Invest*, 125, 3356–64.

Masood S (2016). Neoadjuvant chemotherapy in breast cancers. *Womens Health*, 12, 480–91.

McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM (2016). Clinical diagnosis and management of breast cancer. *J Nucl Med*, 57, 9-16.

Miller E, Lee HJ, Lulla A, et al (2014). Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. *F1000Res*, 3, 1–14.

Nahleh ZA, Barlow WE, Hayes DF, et al (2016). SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. *Breast Cancer Res Treat*, 158, 485–95.

Ostromov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N (2018). CD4 and CD8 T lymphocyte interplay in controlling tumor growth. *Cell Mol Life Sci*, 75, 689–713.

Parekh T, Dodwell D, Sharma N, Shaaban AM (2015). Radiological and pathological predictors of response to neoadjuvant chemotherapy in breast cancer: A Brief Literature Review. *Pathobiology*, 82, 124–32.

Pietrzkowskiz Z, Nemzer B, Sporna A, et al (2010). Influence of betalain-rich extract on reduction of discomfort associated with osteoarthritisa. New Medicine 1, 12-17.

Reddy MK, Alexander-Lindo RL, Nair MG (2005). Relative inhibition of lipid peroxidation, cyclooxygenase enzymes, and human tumor cell proliferation by natural food colors. *J Agric Food Chem*, 53, 9268–73.

Senkus E, Kyriakides S, Ohno S, et al (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 26, 8–30.

Seo AN, Lee HJ, Kim EJ, et al (2013). Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. *Br J Cancer*, 109, 2705–13.

Sharma P(2014). Identification and validation of an anthracycline/ cyclophosphamide-based chemotherapy response assay in breast cancer. *Breast Dis*, 25, 235–37.

Siddik Z(2002). Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. *Cancer J*, 78, 156–62.

Tacar O, Srimornaks P, Dass CR (2013). Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems. *J Pharm Pharmacol*, 65, 157–70.

Tan D, Wang Y, Bai B, Yang X, Han J (2015). Betanin attenuates oxidative stress and inflammatory reaction in kidney of paraquat-treated rat. *Food Chem Toxicol*, 78, 141–6.

Velaei K, Samadi N, Barazvan B, Soleimani RJ (2016). Tumor microenvironment-mediated chemoresistance in breast cancer. *Breast J*, 30, 92–100.

Vidal PJ, López-Nicolás JM, Gandía-Herrero F, García-Carmona F (2014). Inactivation of lipoxygenase and cyclooxygenase by natural betalains and semi-synthetic analogues. *Food Chem*, 154, 246–54.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.